Navigating key news stories in pharma
Subscribe

Featured Stories

Featured
Innovating Inhalation: The Future of Pulmonary and Nasal Drug Delivery
Future Biopharma
Innovating Inhalation: The Future of Pulmonary and Nasal Drug Delivery
Future Biopharma

Non-invasive drug delivery via pulmonary and nasal routes is increasingly in demand; however, while there has already been significant innovation within the sector, even more is required to meet future needs.

Read More →
Future Biopharma
Featured
SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent
SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent

A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.

GSK, LTZ Therapeutics Collaborate on Next-Gen Immunotherapies
GSK, LTZ Therapeutics Collaborate on Next-Gen Immunotherapies

The companies will leverage GSK’s scientific expertise with LTZ’s immune engager platform to develop new first-in-class MCE therapies for the treatment of hematologic cancers and solid tumors.

Gene Therapy Improves Hearing in Children with Profound Genetic Hearing Loss
Gene Therapy Improves Hearing in Children with Profound Genetic Hearing Loss

Regeneron’s investigational gene therapy, DB-OTO, has been found to provide meaningful improvements in hearing for nearly all of the participants in the CHORD clinical trial.

Scientists Discover New Class of Antibiotics that Work Against MDR Bacteria
Scientists Discover New Class of Antibiotics that Work Against MDR Bacteria

Led by researchers at the University of Liverpool, a team of international scientists have discovered a new, potent class of antibiotics that will help in the fight against antimicrobial resistance.

News
Cellular Origins Completes Series A Financing Round
Strategy
Cellular Origins Completes Series A Financing Round
Strategy

The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.

Strategy
ITA Group Acquires UK-Based C2events to Bolster Global Pharma Event Capabilities
Dealmaking
ITA Group Acquires UK-Based C2events to Bolster Global Pharma Event Capabilities
Dealmaking

To strengthen its European presence and enhance high-impact event experiences for life science clients worldwide, ITA Group has acquired C2events, a UK-based event management agency specializing in healthcare and pharmaceutical conferences.

Dealmaking
SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent
R&D
SGS Strengthens RSV Vaccine Research with Launch of Challenge Agent
R&D

A new RSV A-strain challenge agent has been introduced by SGS to enhance CHIM studies and accelerate vaccine development. The breakthrough aims to generate more accurate, data-driven insights into RSV infection and immune response.

R&D

R&D

Expansion

Featured
Novartis Invests in End-to-End Manufacturing in U.S.
Novartis Invests in End-to-End Manufacturing in U.S.

The company is creating a new flagship manufacturing hub in North Carolina that will enable end-to-end manufacturing of its key medicines in one geographic location.

Spinout Ensorcell Launches with Three Flagship Life Science Tools
Spinout Ensorcell Launches with Three Flagship Life Science Tools

Backed by the expert team and cutting-edge resources of Re:Build Manufacturing, Ensorcell will offer innovative, high-quality scientific tools designed to accelerate discoveries and improve patient outcomes.

Wilmington PharmaTech Secures Major Investment to Accelerate Expansion
Wilmington PharmaTech Secures Major Investment to Accelerate Expansion

A significant investment from Curewell Capital has been secured by Wilmington PharmaTech, providing growth capital to expand manufacturing and technology capabilities to accelerate drug development with U.S. manufacturing.

Lilly Grows European Manufacturing Capacity with New Facility in The Netherlands
Lilly Grows European Manufacturing Capacity with New Facility in The Netherlands

The USD 3 billion facility will expand the company’s capacity to produce oral medicines, enabling it to meet rising customer demand, and will also strengthen its global supply chain.

Dealmaking

Featured
ITA Group Acquires UK-Based C2events to Bolster Global Pharma Event Capabilities
ITA Group Acquires UK-Based C2events to Bolster Global Pharma Event Capabilities

To strengthen its European presence and enhance high-impact event experiences for life science clients worldwide, ITA Group has acquired C2events, a UK-based event management agency specializing in healthcare and pharmaceutical conferences.

Strategic Collaboration Forms to Offer Companies Integrated Biopharmaceutical Solutions  
Strategic Collaboration Forms to Offer Companies Integrated Biopharmaceutical Solutions  

A collaboration between Rentschler Biopharma and Coriolis Pharma has been formed that will draw upon complementary scientific and technical expertise to provide end-to-end solutions for the biopharmaceutical value chain.

Partnership Forms to Advance Oral Macrocyclic Peptide Therapies for Immunological Diseases
Partnership Forms to Advance Oral Macrocyclic Peptide Therapies for Immunological Diseases

A strategic research collaboration has been announced by Biogen and Dayra Therapeutics aimed at the discovery and development of oral macrocyclic peptides that could disrupt traditional antibody-based treatments.

Nanoform Establishes New Company and Outlicenses Nanoformulation of Encorafenib
Nanoform Establishes New Company and Outlicenses Nanoformulation of Encorafenib

In collaboration with A.forall and IMGA, Nanoform has formed a new subsidiary aimed at outlicensing Nanoencorafenib as an attractive patient-centric lifecycle management opportunity or value-added generic medicine opportunity.

Strategy

Featured
Cellular Origins Completes Series A Financing Round
Cellular Origins Completes Series A Financing Round

The raised funds, totaling USD 40 million, will be used to accelerate the company’s growth and to advance its robotic platform, Constellation, which enables flexible, scalable cell therapy manufacturing.

Lilly Cuts Price of Tirzepatide Single-dose Vials to Increase Patient Affordability
Lilly Cuts Price of Tirzepatide Single-dose Vials to Increase Patient Affordability

As demand for GLP-1 obesity drugs surges and affordability remains a competitive factor in the global weight-loss market, Eli Lilly slashes tirzepatide vial prices to boost access for self-pay patients.

Meeting New Manufacturing Demands by Investing in Flexibility
Meeting New Manufacturing Demands by Investing in Flexibility

A fundamental, digitally driven overhaul of bio/pharmaceutical manufacturing models are needed to meet the demands of current global supply chain pressures and rising complexity of novel therapeutics.

Beyond the Settlement
Beyond the Settlement

As a settlement is finally agreed upon for Purdue Pharma and the Sackler family, the pharma industry needs to increase transparency and accountability to ensure profits are not prioritized over public health again.

Future Biopharma

Featured
Innovating Inhalation: The Future of Pulmonary and Nasal Drug Delivery
Innovating Inhalation: The Future of Pulmonary and Nasal Drug Delivery

Non-invasive drug delivery via pulmonary and nasal routes is increasingly in demand; however, while there has already been significant innovation within the sector, even more is required to meet future needs.

CPHI Frankfurt 2025: Gaining an Advantage with RTU Cartridges
CPHI Frankfurt 2025: Gaining an Advantage with RTU Cartridges

Primary packaging requirements are evolving in line with development trends; however, flexible and easily integrated ready-to-use solutions are beneficial options, highlight Dr. Robert Lindner and Christoph Zauner from SCHOTT Pharma.

CPHI Frankfurt 2025: Advancing Innovation from Concept to Commercialization
CPHI Frankfurt 2025: Advancing Innovation from Concept to Commercialization

For Jacob Werlinger from Bend Bioscience, turning innovative concepts into reality requires CDMOs to not just be service providers but more of a strategic scientific partner that can help advance the concept to commercialization using the right science tools.

CPHI Frankfurt 2025: Unlocking the Potential of 3D Cell Cultures in Vaccine Production with Novel Nanofiber Platform
CPHI Frankfurt 2025: Unlocking the Potential of 3D Cell Cultures in Vaccine Production with Novel Nanofiber Platform

Implementation of three-dimensional (3D) cell culture nanofiber systems in industrial vaccine production offers much higher viral vaccine titers, greater scalability and improved process economy, but it will require tight collaboration with the industry to help speed up their wide adoption, stresses Laura Chirica from Cellevate.  

Regulatory

Featured
AstraZeneca Gains Nod from FDA for Perioperative Imfinzi-Based Regimen
AstraZeneca Gains Nod from FDA for Perioperative Imfinzi-Based Regimen

The regulator’s decision will provide a new clinical option for patients with early gastric and gastroesophageal cancers that can deliver a significant survival benefit versus chemotherapy alone.

Circio Unveils Next-Generation Circular RNA Expression Platform
Circio Unveils Next-Generation Circular RNA Expression Platform

The company’s circVec 4.0 demonstrates unprecedented gene expression levels in heart and brain tissues to open new therapeutic opportunities across multiple organs.

Nanoform Secures European Commercial CGMP Manufacturing License
Nanoform Secures European Commercial CGMP Manufacturing License

Having secured a European Commercial CGMP Manufacturing License from FIMEA, Nanoform is now able to produce and control the quality of nanoformed APIs for Europe and other key markets.

Staying Ahead of Regulatory Revisions
Staying Ahead of Regulatory Revisions

In light of the evolving therapeutic landscape, increasing use of advanced technologies, and political shifts, regulatory updates are inevitable, meaning that bio/pharma companies will need to adjust quickly to new requirements.

Upcoming Events

Featured
DDL 2025

The Drug Delivery to the Lungs Conference (DDL) is in it’s 36th year and attracts in excess of 1100 attendees worldwide, including scientists, academics, clinicians, regulators and industry experts.

Fierce JPM Week 2026

At Fierce JPM Week 2026, the sector’s most influential leaders, investors and policymakers will convene to confront these questions and chart the course ahead.